Skip to main content
SpringerLink
Log in

Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients.

Methods

One hundred and forty-four patients aged 61–80 years with mild to moderate essential hypertension (DBP ≥95 mmHg and ≤110 mmHg at the end of a 2-week placebo run-in period) were randomly assigned to once daily (o.d.) treatment with valsartan 160 mg (n=73) or enalapril 20 mg (n=71) for 16 weeks. The patients were examined every 4 weeks during the study, with pre-dose BP (standard mercury sphygmomanometer, Korotkoff I and V) and heart rate (pulse palpation) being recorded at each visit. Cognitive function was evaluated at the end of the wash-out period and after 16 weeks of active treatment by means of five tests (verbal fluency, the Boston naming test, word list memory, word list recall and word list recognition).

Results

Both valsartan and enalapril had a clear antihypertensive effect, but the former led to a slightly greater reduction in SBP/DBP at 16 weeks (18.6±4.6/13.7±4.0 mmHg vs 15.6±5.1/10.9±3.9 mmHg; P<0.01). Enalapril did not induce any significant changes in any of the cognitive function test scores; valsartan significantly increased the word list memory score (+11.8%; P<0.05 vs baseline and P<0.01 vs enalapril) and the word list recall score (+18.7%; P<0.05 vs baseline and P<0.01 vs enalapril), but not those of the other tests.

Conclusion

These findings indicate that, in elderly hypertensive patients, 16 weeks of treatment with valsartan 160 mg o.d. is more effective than enalapril 20 mg o.d. in reducing BP, and (unlike enalapril) improves some of the components of cognitive function, particularly episodic memory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Weir MR, Dzau VJ (1999) The renin-angiotensin-aldosterone ssystem:a specific target for hypertension management. Am J Hypertens 12:205S–213S

    Article  CAS  PubMed  Google Scholar 

  2. Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11–34

    CAS  PubMed  Google Scholar 

  3. Nicholls MG, Robertson JI, Inagami T (2001) The renin-angiotensin system in the twenty-first century. Blood Press 10:327–343

    Article  CAS  PubMed  Google Scholar 

  4. Gaard PR (2002) The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 438:1–14

    Article  CAS  PubMed  Google Scholar 

  5. Culman J, Blume A, Gohlke P, Unger T (2002) The renin-angiotensin system in the brain: possible therapeutic implications for AT1-receptor blockers. J Hum Hypertens 16:S64–S70

    Article  CAS  Google Scholar 

  6. Baranowska D, Braszko JJ, Wisniewski K (1983) Effect of angiotensin II on acquisition and extinction of conditioned avoidance in rats. Psychopharmacology 81:247–251

    CAS  PubMed  Google Scholar 

  7. Braszko JJ, Wisniewski K, Kupryszewski G, Witczuk B (1987) Psychotropic effects of angiotensin II and angiotensin III in rat: locomotor and exploratory vs cognitive behaviour. Behav Brain Res 25:195–203

    Article  CAS  PubMed  Google Scholar 

  8. Barnes JM, Barnes NM, Costall B, Horovitz ZP, Naylor RJ (1989) Angiotensin II inhibits the release of (3H)acetylcholine from the rat entorhinal cortex in vitro. Brain Res 492:136–143

    Article  Google Scholar 

  9. Vanhuotte PM (1999) How to assess endothelial function in human blood vessels. J Hypertens 17:1047–1058

    Article  PubMed  Google Scholar 

  10. Skoog I, Lernfeldt B, Landahl S, Palmertz B, Andersson LA, Nilsson L, Persson G (1996) Fifteen-year longitudinal study of blood pressure and dementia. Lancet 347:1141–1145

    CAS  PubMed  Google Scholar 

  11. Alves de Moraes S, Szklo M, Knopman D, Sato R (2002) The relationship between temporal changes in blood pressure and changes in cognitive function. Atherosclerosis Risk in Communities (ARIC) Study. Prev Med 35:258–263

    Article  PubMed  Google Scholar 

  12. Johansson BB (1994) Pathogenesis of vascular dementia: the possible role of hypertension. Dementia 5:174–176

    CAS  PubMed  Google Scholar 

  13. Hanon O, Seux ML, Le Noir H, Rigaud AS, Forette F (2003) Hypertension and dementia. Curr Cardiol Rep 5:435–440

    PubMed  Google Scholar 

  14. Weber MA (1999) Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II antagonists in the treatment of hypertension. Am J Hypertens 12:189S–194S

    Article  CAS  PubMed  Google Scholar 

  15. Petrie MC, Padmanabhan N, McDonald JE et al (2001) Angiotensin converting enzyme (ACE) and non ACE-dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 15:1056–1061

    Article  Google Scholar 

  16. Burnier M, Brunner HR (2000) Angiotensin II receptor antagonists. Lancet 355:637–645

    Article  CAS  PubMed  Google Scholar 

  17. Volpe M, De Paolis P (2000) Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy. Ital Heart J 1:96–103

    CAS  PubMed  Google Scholar 

  18. Flather MD, Yusuf S, Kober L et al (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575–1581

    Article  CAS  PubMed  Google Scholar 

  19. Jong P, Demers C, McKelvie RS, Liu PP (2002) Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 39:463–470

    Article  CAS  PubMed  Google Scholar 

  20. Sleight P (2002) Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 89[Suppl]:11A–17A

  21. Yusuf S (2002) From the HOPE to the ONTARGET and the TRASCEND studies: challenges in improving prognosis. Am J Cardiol 89[Suppl]:18A–26A

  22. Currie D, Lewis RV, McDevitt DG, Nicholson AN, Wright NA (1990) Central effects of the angiotensin converting enzyme inhibitor, captopril. I. Performance and subjective assessment of mood. Br J Clin Pharmacol 30:527–536

    CAS  PubMed  Google Scholar 

  23. Wyss JM, Fisk G, Van Groen T (1992) Impaired learning and memory in mature spontaneosly hypertensive rats. Brain Res 592:135–140

    Article  CAS  PubMed  Google Scholar 

  24. Starr JM, Whalley LJ (1994) ACE-inhibitors: central actions. Raven Press, New York

  25. Tedesco MA, Ratti G, Mennella S et al (1999) Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 12:1130–1134

    Article  CAS  PubMed  Google Scholar 

  26. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P (2003) Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients. J Hum Hypertens 17:781–785

    Article  CAS  PubMed  Google Scholar 

  27. Elliot WJ (2000) The therapeutic trials comparing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Res 2:402–411

    Google Scholar 

  28. Smith DHG, Neutel JM, Morgenstern P (1998) Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 15:229–240

    CAS  Google Scholar 

  29. Markham A, Goa KL (1997) Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54:299–311

    CAS  PubMed  Google Scholar 

  30. Fogari R, Zoppi A, Mugellini A, Preti P, Banderali A, Pesce RM, Vanasia A (1999) Comparative efficacy of losartan and valsartan in mild to moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Curr Ther Res 60:195–206

    Article  CAS  Google Scholar 

  31. Starr JM, Whalley LJ (1992) Senile hypertension and cognitive impairment. An overview. J Hypertens 10[Suppl]:S31–S42

  32. Hansson L, Hedner T, Dahlof B (1992) Prospective, randomized, open-label, blinded-endpoint (PROBE) study. A novel design for intervention trials. Blood Press 1:113–114

    CAS  PubMed  Google Scholar 

  33. Isaacs B, Kennie AT (1973) The SET test as an aid to the detection of dementia in old people. Br J Psychiatry 123:467–470

    CAS  PubMed  Google Scholar 

  34. Tranel D (1992) Neuropsychological assessment. Psychiatr Clin North Am 15:283–299

    CAS  Google Scholar 

  35. Kaplan EF, Goodglass H, Weinstraub S (1978) The Boston Naming Test. Veterans Administration Medical Center, Boston

  36. Morris JC, Heyman A, Mohs RC et al (1989) The consortium to establish a registry for Alzheimer’s disease (CERAD). Part 1. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 39:1159–1165

    CAS  PubMed  Google Scholar 

  37. Mohs RC, Kim Y, Johns CA et al (1986) Assessing change in Alzheimer’s disease: memory and language tests. In: Poon LW (ed) Handbook for clinical memory assessment of older adults. American Psychological Association, Washington, pp 149–155

  38. Cuocolo A, Storto G, Izzo R (1999) Effects of valsartan on left ventricular diastolic function in patients with mild to moderate essential hypertension : comparison with enalapril. J Hypertens 17:1759–1766

    Article  CAS  PubMed  Google Scholar 

  39. Siragy HM (2002) Angiotensin receptor blockers: how important is selectivity? Am J Hypertens 15:1006–1014

    Article  CAS  PubMed  Google Scholar 

  40. Squire LR (1987) Memory and brain. Oxford University Press, Oxford

  41. Lezak MD (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, New York

  42. Cabeza R, Nyberg L (1997) Imaging cognition: an empirical review of PET studies with normal subjects. J Cogn Neurosci 9:1–26

    Google Scholar 

  43. Fahlander K, Wahlin A, Fastbom J, Grut M, Forsell Y, Hill R et al (2000) The relationship between signs of cardiovascular deficiency and cognitive performance in old age: a population-based study. J Gerontol B Psychol Sci Soc Sci 55:P259–P265

    CAS  PubMed  Google Scholar 

  44. Backman L, Small B, Wahlin A, Larsson M (1999) Cognitive functioning in very old age. In: Cruik FIM, Salthouse TA (eds) The handbook of aging and cognition, 2nd edn. Erlbaum, Muhwah, NJ, pp 499–558

  45. Raghawendra V, Chopra K, Kulkarni SK (2001) Comparative studies of the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 35:65–69

    Article  PubMed  Google Scholar 

  46. Barnes NM, Champaneria S, Costall B, Kelly ME, Murphy DA (1990) Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport 1:239–242

    CAS  PubMed  Google Scholar 

  47. Okuyama S, Sakagawa T, Inagami T (1999) Role of the angiotensin II type 2 receptor in the mouse central nervous system. Jpn J Pharmacol 81:259–263

    Article  CAS  PubMed  Google Scholar 

  48. Wright JW, Stubley LA, Pederson ES, Kramar EA, Hanesworth J, Harding JW (1999) Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 19:3952–3961

    CAS  PubMed  Google Scholar 

  49. Chai SY, Bastias MA, Clune EF et al (2000) Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography. J Chem Neuroanat 20:339–348

    Google Scholar 

  50. Pederson ES, Krishnan R, Harding JW, Wright JW (2001) A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul Pept 102:147–156

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Therapeutics, Centro Ipertensione e Fisiopatologia Cardiovascolare, Clinica Medica II, IRCCS Policlinico S. Matteo, University of Pavia, Piazzale Golgi 2, 27100 , Pavia, Italy

    Roberto Fogari, Amedeo Mugellini, Annalisa Zoppi, Gianluigi Marasi, Carlo Pasotti, Luigi Poletti, Andrea Rinaldi & Paola Preti

Authors
  1. Roberto Fogari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amedeo Mugellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annalisa Zoppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gianluigi Marasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlo Pasotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luigi Poletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Rinaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paola Preti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Fogari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fogari, R., Mugellini, A., Zoppi, A. et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 59, 863–868 (2004). https://doi.org/10.1007/s00228-003-0717-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-003-0717-9

Keywords

Search

Navigation